 <h1>Byetta Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>exenatide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about exenatide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Byetta.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to exenatide: subcutaneous powder for suspension extended release, subcutaneous solution, subcutaneous suspension extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Powder for Suspension, Extended Release; Suspension, Extended Release)</p><p>Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether exenatide extended-release causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined.Exenatide extended-release is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of exenatide extended-release and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with exenatide extended-release</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, exenatide (the active ingredient contained in Byetta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking exenatide:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>bloated or feeling of fullness</li>
<li>chills</li>
<li>confusion</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased awareness or responsiveness</li>
<li>decreased urination or urine output</li>
<li>depression</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives or welts, itching, or skin rash</li>
<li>hostility</li>
<li>increase in heart rate</li>
<li>indigestion</li>
<li>irritability</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>muscle twitching</li>
<li>nausea</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid breathing</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe sleepiness</li>
<li>sunken eyes</li>
<li>swelling of the face, ankles, or hands</li>
<li>thirst</li>
<li>tightness in the chest</li>
<li>unusual bleeding or bruising</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
<li>vomiting</li>
<li>wrinkled skin</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking exenatide:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>cold sweats</li>
<li>cool, pale skin</li>
<li>increased hunger</li>
<li>nervousness</li>
<li>nightmares</li>
<li>severe vomiting</li>
<li>shakiness</li>
<li>slurred speech</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of exenatide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>diarrhea</li>
<li>feeling jittery</li>
<li>heartburn</li>
<li>stomach discomfort or upset</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Decreased appetite</li>
<li>increased sweating</li>
<li>lack or loss of strength</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Change in taste</li>
<li>excess air or gas in the stomach or bowels</li>
<li>loss of taste</li>
<li>passing gas</li>
<li>pressure in the stomach</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>redness of the skin</li>
<li>sleepiness or unusual drowsiness</li>
<li>swelling of the abdomen or stomach area</li>
</ul><p>
<!-- end subcutaneous powder for suspension extended release, subcutaneous solution, subcutaneous suspension extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to exenatide: subcutaneous powder for injection extended release, subcutaneous solution, subcutaneous suspension extended release</i></p><h3>General</h3><p>The most commonly reported side effects have included nausea, vomiting, diarrhea, injection site pruritus, and injection site nodules.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Generalized pruritus and/or urticaria, macular or papular rash, angioedema, anaphylactic reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-exenatide (the active ingredient contained in Byetta) antibodies (up to 90%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Decreased appetite, rapid weight loss (greater than 3.3 lbs/1.5 kg a week), anorexia, hypokalemia</p>
<p><b>Rare</b> (less than 0.1%): Dehydration (associated with nausea, vomiting and/or diarrhea)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p>
<p><b>Postmarketing reports</b>: Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection-site reactions (up to 17.1%)</p>
<p><b>Common</b> (1% to 10%): Injection-site pain, injection site pruritus, injection site erythema<sup>[Ref]</sup></p><p>During clinical trials for the exenatide auto-injector (Bydureon BCISE[R]), injection site nodule was the most commonly reported adverse reaction reported in 10.5% of patients (n=526).  Injection site pruritus and injection site erythema were reported in 3.2% and 2.3% of patients, respectively.  Injection site nodule was reported as the reason for discontinuation in 0.5% of patients.  </p>
<p></p>
<p>Clinical trials comparing immediate-release (Byetta[R]) and extended-release (Bydureon[R]) exenatide have shown that injection-site reactions occurred more frequently in patients treated with extended-release (17.1% vs 12.7%).<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 34%), diarrhea (up to 13%), vomiting (up to 19%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Intestinal obstruction</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, constipation, gastroesophageal reflux disease, abdominal distension, abdominal pain, upper abdominal pain, abdominal discomfort, toothache, viral gastroenteritis, gastroenteritis</p>
<p><b>Very rare</b> (less than 0.01%): Ileus, ischemic colitis, gut ischemia</p>
<p><b>Postmarketing reports</b>: Eructation, flatulence, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death<sup>[Ref]</sup></p><p>In clinical trials with the extended-release auto-injector, acute pancreatitis occurred in 0.4% of patients.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Increased heart rate (up to 15%)</p>
<p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><p>Increases in heart rate of up to 4.5 beats per minute have been observed; long-term effects of increases in heart rate have not been established.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Hyperhidrosis</p>
<p>Rare (less than 0.1%) Alopecia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint pain, back pain, arthralgia, pain in extremity, musculoskeletal pain, muscle spasms<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, diabetic neuropathy</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p>
<p><b>Rare</b> (less than 0.1%): Somnolence<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia, anxiety<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (up to 19%), upper respiratory tract infection (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Sinusitis, influenza, cough, oropharyngeal pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia, feeling jittery<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Increased INR with concomitant warfarin therapy, sometimes associated with bleeding</p>
<p><b>Postmarketing reports</b>: Drug-induced thrombocytopenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Bydureon BCise (exenatide)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_2">2. "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Byetta (exenatide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>81 Reviews</li>
<li>Drug class: incretin mimetics</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Byetta &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Bydureon, Bydureon BCise</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to exenatide: subcutaneous powder for injection extended release, subcutaneous solution, subcutaneous suspension extended release</i></p><h3>General</h3><p>The most commonly reported side effects have included nausea, vomiting, diarrhea, injection site pruritus, and injection site nodules.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Generalized pruritus and/or urticaria, macular or papular rash, angioedema, anaphylactic reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-exenatide (the active ingredient contained in Byetta) antibodies (up to 90%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (up to 19%)</p><p><b>Common</b> (1% to 10%): Decreased appetite, rapid weight loss (greater than 3.3 lbs/1.5 kg a week), anorexia, hypokalemia</p><p><b>Rare</b> (less than 0.1%): Dehydration (associated with nausea, vomiting and/or diarrhea)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><p><b>Postmarketing reports</b>: Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection-site reactions (up to 17.1%)</p><p><b>Common</b> (1% to 10%): Injection-site pain, injection site pruritus, injection site erythema<sup>[Ref]</sup></p><p>During clinical trials for the exenatide auto-injector (Bydureon BCISE[R]), injection site nodule was the most commonly reported adverse reaction reported in 10.5% of patients (n=526).  Injection site pruritus and injection site erythema were reported in 3.2% and 2.3% of patients, respectively.  Injection site nodule was reported as the reason for discontinuation in 0.5% of patients.  </p><p></p><p>Clinical trials comparing immediate-release (Byetta[R]) and extended-release (Bydureon[R]) exenatide have shown that injection-site reactions occurred more frequently in patients treated with extended-release (17.1% vs 12.7%).<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 34%), diarrhea (up to 13%), vomiting (up to 19%)</p><p><b>Uncommon</b> (0.1% to 1%): Intestinal obstruction</p><p><b>Common</b> (1% to 10%): Dyspepsia, constipation, gastroesophageal reflux disease, abdominal distension, abdominal pain, upper abdominal pain, abdominal discomfort, toothache, viral gastroenteritis, gastroenteritis</p><p><b>Very rare</b> (less than 0.01%): Ileus, ischemic colitis, gut ischemia</p><p><b>Postmarketing reports</b>: Eructation, flatulence, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death<sup>[Ref]</sup></p><p>In clinical trials with the extended-release auto-injector, acute pancreatitis occurred in 0.4% of patients.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Increased heart rate (up to 15%)</p><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><p>Increases in heart rate of up to 4.5 beats per minute have been observed; long-term effects of increases in heart rate have not been established.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Hyperhidrosis</p><p>Rare (less than 0.1%) Alopecia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Joint pain, back pain, arthralgia, pain in extremity, musculoskeletal pain, muscle spasms<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, diabetic neuropathy</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia</p><p><b>Rare</b> (less than 0.1%): Somnolence<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia, anxiety<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (up to 19%), upper respiratory tract infection (up to 17%)</p><p><b>Common</b> (1% to 10%): Sinusitis, influenza, cough, oropharyngeal pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia, feeling jittery<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Increased INR with concomitant warfarin therapy, sometimes associated with bleeding</p><p><b>Postmarketing reports</b>: Drug-induced thrombocytopenia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Bydureon BCise (exenatide)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_2">2. "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Byetta (exenatide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>81 Reviews</li>
<li>Drug class: incretin mimetics</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Byetta &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>